# A Study of Pomadomide in Combination With Rituximab and Methotrexate for Newly-diagnosed Primary Central Nervous System Lymphoma

> **NCT06554561** · PHASE1,PHASE2 · RECRUITING · sponsor: **Second Affiliated Hospital, School of Medicine, Zhejiang University** · enrollment: 43 (estimated)

## Conditions studied

- PCNSL

## Interventions

- **DRUG:** Pomalidomide
- **DRUG:** Rituximab
- **DRUG:** Methotrexate

## Key facts

- **NCT ID:** NCT06554561
- **Lead sponsor:** Second Affiliated Hospital, School of Medicine, Zhejiang University
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-08-31
- **Primary completion:** 2026-08-31
- **Final completion:** 2029-08-31
- **Target enrollment:** 43 (ESTIMATED)
- **Last updated:** 2024-08-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06554561

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06554561, "A Study of Pomadomide in Combination With Rituximab and Methotrexate for Newly-diagnosed Primary Central Nervous System Lymphoma". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT06554561. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*